Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 2/20 | 0.70 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | OPA1 | O60313 | 1/20 | 0.39 |
| ▸ | EIF5B | O60841 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260014 | 0.87 | HTR2A (0.65) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL6327455 | 0.83 | HTR2A (0.60) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL10199629 | 0.82 | HTR2A (1.00) | HTR2AHTR2CMTNR1AMTNR1BOPA1 | |
| SCHEMBL12312046 | 0.82 | HTR2A (0.59) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL9303578 | 0.80 | HTR2A (0.63) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL12450045 | 0.80 | HTR2A (0.74) | HTR2AHTR2CMTNR1AMTNR1BKMT2A | |
| SCHEMBL15024522 | 0.79 | HTR2A (0.69) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL12572732 | 0.78 | HTR2A (0.60) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL9079125 | 0.77 | HTR2A (0.89) | HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL2348471 | 0.77 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801969-B | Indolyl pyrrolidines for the treatment of cancer | ARQULE, INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| CN-101801969-A | The indolyl pyrrolidines of treatment cancer | ARQULE INC | 2010-08-11 | — | — | CN | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2173748-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | HTR2A 3002/4885HTR2C 2060/4885MTNR1A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.